Glaxo pandemic flu vaccine works better than rivals’


GlaxoSmithKline Plc's vaccine against a bird flu virus that may spark a pandemic was effective in about 80% of people who received it in tests, indicating the shot is more effective than those of rivals. The shot was effective at a small dose using a new additive to boost effectiveness, the London-based drugmaker said in an e-mailed statement today. Paris-based Sanofi-Aventis SA has said its experimental vaccine was only 50% effective. Glaxo, Europe's biggest drugmaker, is testing two bird flu inoculations in people, including one with a standard additive. About 30 companies worldwide including Novartis AG's Chiron unit are working on such products as world health officials track the lethal H5N1 strain of avian flu.
Glaxo said its H5N1 vaccine uses a new additive, or adjuvant, to get a strong immune response at a low dose. The adjuvant augments the vaccine's potency, allowing a smaller dose of the immunization to be given and increasing the amount of people who can be inoculated in the event of a pandemic. Glaxo is also testing a shot with a standard aluminum-based additive. Adjuvants, from the Latin word „to help,” are substances used to enhance the ability of an antigen to stimulate the immune system.
At least 133 of the 231 people known to be infected with H5N1 have died, according to the World Health Organization in Geneva. A new death toll was reported this morning from Taiwan, where a young boy died of the infection. (Bloomberg)

MET Group Wins TXF 'Commodity Financing Deal of the Year' Energy Trade

MET Group Wins TXF 'Commodity Financing Deal of the Year'

Polish Unemployment Falls in April World

Polish Unemployment Falls in April

1st Phase of Hungaroring Upgrade Completed Construction

1st Phase of Hungaroring Upgrade Completed

Tourism Nights Spent in Hungary Down Slightly in April Tourism

Tourism Nights Spent in Hungary Down Slightly in April


Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.